GYS1 is one of the major regulators of glycogen synthesis, and the inhibition of GYS1 leads to the accumulation of glycogen in glioblastoma cells, resulting in the inhibition of proliferation and migration and the formation of ROS, which suggests that the inhibition of GYS1 may be a promising therapeutic target for gliomas [106]. The gene discussed is GYS1; the disease is central nervous system cancer.